PT - JOURNAL ARTICLE AU - Andrade Sierra Jorge AU - Delgado Astorga Claudia AU - Nava Vargas Miriam Gabriela AU - Rojas Campos Enrique AU - Arellano Arteaga Kevin Javier AU - Hernández Morales Karla AU - Carlos A Andrade Castellanos AU - Andrade-Ortega Antonio de Jesús AU - González-Correa Luis Gerardo TI - Procalcitonin and High APACHE Scores are Associated with the Development of Acute Kidney Injury in Patients with SARS-CoV-2 AID - 10.1101/2022.08.09.22274874 DP - 2022 Jan 01 TA - medRxiv PG - 2022.08.09.22274874 4099 - http://medrxiv.org/content/early/2022/08/10/2022.08.09.22274874.short 4100 - http://medrxiv.org/content/early/2022/08/10/2022.08.09.22274874.full AB - Background Acute kidney injury (AKI) is associated with poor outcomes in patients infected with SARS-CoV-2. Sepsis, direct injury to kidney cells by the virus, and severe systemic inflammation are mechanisms implicated in its development. We investigated the association between inflammatory markers (C-reactive protein, procalcitonin, D-dimer, lactate dehydrogenase, and ferritin) in patients infected with SARS-CoV-2 and the development of AKI.Methods A prospective cohort study performed at the Civil Hospital (Dr. Juan I. Menchaca) Guadalajara, Mexico, included patients aged >18 years with a diagnosis of SARS-CoV-2 pneumonia confirmed by RT-PCR and who did or did not present with AKI (KDIGO) while hospitalized. Biomarkers of inflammation were recorded, and kidney function was estimated using the CKD-EPI formula.Results 291 patients were included (68% men; mean age, 57 years). The incidence of AKI was 40.5% (118 patients); 21% developed stage 1 AKI, 6% developed stage 2 AKI, and 14% developed stage 3 AKI. The development of AKI was associated with phosphate higher (p = 0.002) (RR 1.39, CI 95% 1.13 – 1.72), high procalcitonin levels at hospital admission (p = 0.005) (RR 2.09, CI 95% 1.26-3.50), and high APACHE scores (p = 0.011) (RR 2.0, CI 95% 1.17-3.40). The survival analysis free of AKI according to procalcitonin levels and APACHE scores demonstrated a lower survival in patients with procalcitonin >0.5 ng/ml (p= 0.001) and APACHE >15 points (p = 0.004).Conclusions phosphate, high procalcitonin levels, and APACHE scores >15 were predictors of AKI development in patients hospitalized with COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Hospital Civil de Guadalajara, and Dr. Juan I Menchaca gave ethical approval for this work. Registration number: 17CI14 039 116 COFEPRISI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesMost clinical data are restricted to protecting information from misuse. The data may be shared by the OPD, Hospital Civil de Guadalajara, and Dr. Juan I Menchaca (HCG-JIM) after approval from the Ethics Committee of the Institution. The data supporting the findings of this study are available from the corresponding author upon reasonable request.COVID-19Coronavirus 2019SAHSystemic arterial hypertensionDMDiabetes mellitusAKIAcute kidney injuryCRPC-reactive proteinPCTProcalcitoninLDHLactate dehydrogenaseALTAlanine aminotransferaseSCrSerum creatinineCRRTContinuous Renal Replacement TherapyRT-PCRReverse Transcriptase Polymerase Chain ReactionKDIGOKidney Disease Improving Global OutcomesAPACHE IIAcute Physiology and Chronic Health Evaluation IISOFASequential Organ Failure AssessmenteGFREstimated glomerular filtration rateCKDChronic Kidney DiseasePaO2/FiO2Oxygen to fraction of inspired oxygenBMIBody Mass IndexIMVInvasive mechanical ventilationACEiAngiotensin-converting Enzyme InhibitorsARBsAngiotensin receptor blockersNGALNeutrophil gelatinase-associated lipocalinKIM-1Kidney injury molecule 1